First patient for FRAIL-M trial

FRAIL-M, a frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma, has enrolled its first patient. This trial uses MRDR infrastructure to facilitate recruitment of sites and data collection, and will identify which competing treatment options are more appropriate in transplant-ineligible myeloma patients according to frailty status. FRAIL-M is conducted by the Australasian Myeloma Research Consortium (AMARC) and sponsored by the Australasian Leukaemia and Lymphoma Group (ALLG).